Delayed catabolism of apoB-48 lipoproteins due to decreased heparan surfate proteoglycan production in diabetic mice

Journal of Clinical Investigation

Volumn 105, Issue 12, 2000, Pages 1807-1818

  Ebara, Tetsu ^a   Conde, Karin ^a   Kako, Yuko ^a   Liu, Yanzhu ^a   Xu, Yan ^a   Ramakrishnan, Rajasekhar ^a   Goldberg, Ira J ^a   Shachter, Neil S ^a,b  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; PROTEOHEPARAN SULFATE; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; GLYCOPROTEIN SYNTHESIS; INSULIN DEPENDENT DIABETES MELLITUS; LIPOLYSIS; LIPOPROTEIN METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

EID: 0033917880     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI8283     Document Type: Article

References (91)

1. Królewski, A.S., et al. 1987. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am. J. Cardiol. 59:750-755.
2. Jensen, T., Borch-Johnsen, K., Kofoed-Enevoldsen, A., and Deckert, T. 1987. Coronary heart disease in young Type I (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia. 30:144-148.
3. Winocour, P.H., Durrington, P.N., Ishola, M., Hillier, V.F., and Anderson, D.C. 1989. The prevalence of hyperlipidemia and related clinical features in insulin-dependent diabetes mellitus. Q. J. Med. 70:265-276.
4. 1992. Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. The DCCT Research Group. Diabetes Care. 15:886-894.
5. Rivellese, A., et al. 1988. Presence of very low density lipoprotein compositional abnormalities in Type I (insulin-dependent) diabetic patients; effects of blood glucose optimisation. Diabetologia. 31:884-888.
6. Patti, L., et al. 1993. Abnormal distribution of VLDL subfractions in Type I (insulin-dependent) diabetic patients: could plasma lipase activities play a role? Diabetologia. 36:155-160.
7. Perez, A., et al. 1997. Lipoprotein compositional abnormalities in Type I diabetes: effect of improved glycaemic control. Diabetes Res. Clin. Pract. 36:83-90.
8. Dunn, F.L. 1992. Plasma lipid and lipoprotein disorders in IDDM. Diabetes. 41(Suppl. 2):102-106.
9. f 100-400 plasma lipoproteins in insulin-dependent diabetes mellitus. J. Lipid Res. 32:1133-1141.
10. Phillips, N.R., Waters, D., and Havel, R.J. 1993. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 88:2762-2770.
11. Groot, P.H.E., et al. 1991. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler. Thromb. 11:653-662.
12. Ginsberg, H.N., et al. 1995. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler. Thromb. Vasc. Biol. 15:1829-1838.
13. Sharrett, A.R., Chambless, L.E., Heiss, G., Paton, C.C., and Patsch, W. 1995. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler. Thromb. Vasc. Biol. 15:2122-2129.
14. Cooper, A.D. 1997. Hepatic uptake of chylomicron remnants. J. Lipid Res. 38:2173-2192.
15. Fried, S.K., Russell, C.D., Grauso, N.L., and Brolin, R.E. 1993. Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. J. Clin. Invest. 92:2191-2198.
16. Ginsberg, H.N. 1991. Lipoprotein physiology in nondiabetic and diabetic states: relationship to atherogenesis. Diabetes Care. 14:839-855.
17. Eckel, R.H., Goldberg, I.J., Steiner, L., Yost, T.J., and Paterniti, J.R. 1988. Plasma lipolytic activity. Relationship to postheparin lipolytic activity and evidence for metabolic regulation. Diabetes. 37:610-615.
18. Tsutsumi, K., Inoue, Y., Shima, A., and Murase, T. 1995. Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats. Diabetes. 44:414-417.
19. Shimada, M., et al. 1995. Overexpression of human lipoprotein lipase protects diabetic transgenic mice from diabetic hypertriglyceridemia and hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 15:1688-1694.
20. Li, W.W., et al. 1995. Common genetic variation in the promoter of the human apoC-III gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J. Clin. Invest. 96:2601-2605.
21. Brown, W.V., and Baginsky, M.L. 1972. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem. Biophys. Res. Commun. 46:375-382.
22. Havel, R.J., et al. 1973. Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoprotein lipase from different sources. Biochemistry. 12:1828-1833.
23. Ebara, T., Ramakrishnan, R., Steiner, G., and Shachter, N.S. 1997-Chylomicronemia due to apolipoprotein C-III overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J. Clin. Invest. 99:2677-2681.
24. Kowal, R.C., et al. 1990. Opposing effects of apolipoprotein E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J. Biol. Chem. 265:10771-10779.
25. Windler, E.E., et al. 1980. The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J. Biol. Chem. 255:10464-10471.
26. Sehayek, E., and Eisenberg, S. 1991. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J. Biol. Chem. 266:18259-18267.
27. Al Muhtaseb, N., Al Yousuf, A.R., and Bajaj, J.S. 1992. Apolipoprotein A-I, A-II, B, C-II, and C-III in children with insulin-dependent diabetes mellitus. Pediatrics. 89:936-941.
28. Al-Muhtaseb, N., Al-Yusef, A.R., and Bajaj, J.S. 1991. Lipoprotein lipids and apolipoproteins (AI, AII, B, CII, CIII) in Type 1 and Type 2 diabetes mellitus in young Kuwaiti women. Diabet. Med. 8:732-737.
29. Rubinsztein, D.C., et al. 1990. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J. Clin. Invest. 86:1306-1312.
30. Hui, D.Y., Innerarity, T.L., and Mahley, R.W. 1981. Lipoprotein binding to canine hepatic membranes. Metabolically distinct apoE and apoB,E receptors. J. Biol. Chem. 256:5646-5655.
31. Kita, T., et al. 1982. Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism genetically distinct from the low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA. 9:3623-3627.
32. Herz, J., et al. 1988. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J. 7:4119-4127.
33. Kowal, R.C., Herz, J., Goldstein, J.L., Esser, V., and Brown, M.S. 1989. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc. Natl. Acad. Sci. USA. 86:5810-5814.
34. Misra, U.K., Gawdi, G., Gonzalez-Gronow, M., and Pizzo, S.V. 1999. Coordinate regulation of the α2-macroglobulin signaling receptor and the low density lipoprotein receptor-related protein/α2-macroglobulin receptor by insulin. J. Biol. Chem. 274:25785-25791.
35. Curtin, A., et al. 1996. Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48. Acta Diabetol. 33:205-210.
36. Karpe, F., Hellenius, M.L., and Hamsten, A. 1999. Differences in post-prandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease Metabolism. 48:301-307.
37. Farese, R.V., Jr., et al. 1996. Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. Proc. Natl. Acad. Sci. USA. 93:6393-6398.
38. Véniant, M.M., et al. 1998. Lipoprotein clearance mechanisms in LDL receptor-deficient "apoB-48-only" and "apoB-100-only" mice. J. Clin. Invest. 102-1559-1568.
39. Kunjathoor, V.V., Wilson, D.L., and LeBoeuf, R.C. 1996. Increased atherosclerosis in streptozotocin-induced diabetic mice. J. Clin. Invest. 97:1767-1773.
40. Havel, R.J., Eder, H.A., and Bragdon, J.H. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34:1345-1353.
41. Shachter, N.S., et al. 1996. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein C-I. J. Clin. Invest. 98:846-855.
42. de Silva, H.V., et al. 1994. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J. Biol. Chem. 269:2324-2335.
43. McCormick, S.P., et al. 1996. Transgenic mice that overexpress mouse apolipoprotein B. Evidence that the DNA sequences controlling intestinal expression of the apolipoprotein B gene are distant from the structural gene. J. Biol. Chem. 271:11963-11970.
44. Smith, J.D., Plump, A.S., Hayek, T., Walsh, A., and Breslow, J.L. 1990. Accumulation of human apolipoprotein E in the plasma of transgenic mice. J. Biol. Chem. 265:14709-14712.
45. Chen, M., Breslow, J.L., Li, W., and Leff, T. 1994. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J. Lipid Res. 35:1918-1924.
46. Aalto-Setälä, K., et al. 1992. Mechanism of hypertriglyceridemia in human apo CIII transgenic mice: diminished VLDL fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J. Clin. Invest. 90:1889-1900.
47. Jong, M.C., et al. 1996. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3 Leiden and human apolipoprotein CI. Arterioscler. Thromb. Vasc. Biol. 16:934-940.
48. Baginsky, M.L., and Brown, W.V. 1977. Differential characteristics of purified hepatic triglyceride lipase and lipoprotein lipase from human postheparin plasma. J. Lipid Res. 18:423-437.
49. Paigen, B., Morrow, A., Brandon, C., Mitchell, D., and Holmes, P. 1985. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis. 57:65-73.
50. Bilheimer, D.W., Eisenberg, J., and Levy, R.I. 1972. The metabolism of very low density lipoproteins. I. Preliminary in vivo and in vitro observations. Biochim. Biophys. Acta. 26:212-221.
51. Ramakrishnan, R., Arad, Y., Wong, S., and Ginsberg, H.N. 1990. Nonuniform radiolabeling of VLDL apolipoprotein B: implications for the analysis of studies of the kinetics of the metabolism of lipoproteins containing apolipoprotein B. J. Lipid Res. 31:1031-1042.
52. Wu, S.M., Boyer, C.M., and Pizzo, S.V. 1997. The binding of receptor-recognized α2-macroglobulin to the low density lipoprorein receptor-related protein and the α2M signaling receptor is decoupled by oxidation. J. Biol. Chem. 272:20627-20635.
53. Paka, L., Kako, Y., Obunike, J.C., and Pillarisetti, S. 1999. Apolipoprotein E containing high density lipoprotein stimulates endothelial production of heparan sulfate rich in biologically active heparin-like domains. A potential mechanism for the anti-atherogenic actions of vascular apolipoprotein E. J. Biol. Chem. 274:4816-4823.
54. Pillarisetti, S., Klein, M.G., and Goldberg, I.J. 1992. Identification of a heparin-releasable lipoprotein lipase binding protein from endothelial cells. J. Biol. Chem. 267:16517-16522.
55. Obunike, J.C., Pillarisetti, S., Paka, L., Low, M.G., and Goldberg, I.J. 1996. Lipoprotein lipase degradation by adipocytes: receptor-associated protein (RAP)-sensitive and proteoglycan-mediated pathways. J. Lipid Res. 37:2439-2449.
56. Obunike, J.C., et al. 2000. The heparin-binding proteins apolipoprotein E and lipoprotein lipase enhance cellular proteoglycan production. Arterioscler. Thromb. Vasc. Biol. 20:111-118.
57. Wagner, W.D., and Nohlgren, S.R. 1981. Aortic glycosaminoglycans in genetically selected WC-2 pigeons with increased atherosclerosis susceptibility. Arteriosclerosis. 1:192-201.
58. Choi, S.Y., and Cooper, A.D. 1993. A comparison of the roles of the low density lipoprotein (LDL) receptor and the LDL receptor-related protein/2-macroglobulin receptor in chylomicron remnant removal in the mouse in vivo. J. Biol. Chem. 268:15804-15811.
59. Roskams, T., et al. 1995. Heparan sulfate proteoglycan expression in normal human liver. Hepatology. 21:950-958.
60. Kako, Y., et al. 1999. Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice. Effects on lipoproteins and atherosclerosis. J. Lipid Res. 40:2185-2194.
61. Bar-on, H., Chen, Y., and Reaven, G. 1981. Evidence for a new cause of defective plasma removal of very low density lipoproteins in insulin-deficient rats. Diabetes 30:496-499.
62. Laakso, M., et al. 1987. Relationship between postheparin plasma lipases and high-density lipoprotein cholesterol in different types of diabetes. Diabetologia. 30:703-706.
63. Hansen, P.M., et al. 1997. Skeletal muscle lipoprotein-lipase activity in insulin-dependent diabetic patients with and without albumin-uria. J. Diabetes Complications. 11:230-235.
64. Donner, C., et al. 1998. Accelerated lipoprotein uptake by transplantable hepatomas that express hepatic lipase. J. Lipid Res. 39:1805-1815.
65. Hegele, R.A., et al. 1998. Elevated LDL triglyceride concentrations in subjects heterozygous for the hepatic lipase S267F variant. Arterioscler. Thromb. Vasc. Biol. 18:1212-1216.
66. Boisfer, E., et al. 1999. Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis. J. Biol. Chem. 274:11564-11572.
67. Weisgraber, K.H., et al. 1990. Apolipoprotein C-I modulates the interaction of apolipoprotein E with β-migrating very low density lipoproteins (β-VLDL) and inhibits binding of β-VLDL to low density lipoprotein receptor-related protein. J. Biol. Chem. 265:22453-22459.
68. Jong, M.C., et al. 1996. In the absence of the low density lipoprotein receptor, human apolipoprotein C-I overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J. Clin. Invest. 98:2259-2267.
69. Mahley, R.W., and Ji, Z.-S. 1999. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40:1-16.
70. Ji, Z.S., Sanan, D.A., and Mahley, R.W. 1995. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J. Lipid Res. 36:583-592.
71. Willnow, T.E., Sheng, Z., Ishibashi, S., and Herz, J. 1994. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science. 264:1471-1474.
72. Rohlmann, A., Gotthardt, M., Hammer, R.E., and Herz, J. 1998. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J. Clin. Invest. 101:689-695.
73. Ishibashi, S., Herz, J., Maeda, N., Goldstein, J.L., and Brown, M.S. 1994. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc. Natl. Acad. Sci. USA. 91:4431-4435.
74. Ji, Z.-S., et al. 1993. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J. Biol. Chem. 268:10160-10167.
75. Al-Haideri, M., et al. 1997. Heparan sulfate proteoglycan-mediated uptake of apolipoprotein E-triglyceride-rich lipoprotein particles: a major pathway at physiological particle concentrations. Biochemistry. 36:12766-12772.
76. Kjellen, L., Bielefeld, D., and Hook, M. 1983. Reduced sulfation of liver heparan sulfate in experimentally diabetic rats. Diabetes. 32:337-342.
77. Spiro, M.J. 1987. Sulfate metabolism in the alloxan-diabetic rat: relationship of altered sulfate pools to proteoglycan sulfation in heart and other tissues. Diabetologia. 30:259-267.
78. Unger, E., Pettersson, I., Eriksson, U.J., Lindahl, U., and Kjellen, L. 1991. Decreased activity of the heparan sulfate-modifying enzyme glucosaminyl N-deacetylase in hepatocytes from streptozotocin-diabetic rats. J. Biol. Chem. 266:8671-8674.
79. Kofoed-Enevoldsen, A., Noonan, D., and Deckert, T. 1993. Diabetes mellitus induced inhibition of glucosaminyl N-deacetylase: effect of short-term blood glucose control in diabetic rats. Diabetologia. 36:310-315.
80. Park, L., et al. 1998. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat. Med. 4:1025-1031.
81. Rescan, P.Y., et al. 1993. Distribution and origin of the basement membrane component perlecan in rat liver and primary hepatocyre culture. Am. J. Pathol. 142:199-208.
82. van der Woude, F.J., and van Det, N.F. 1997. Heparan sulphate proteoglycans and diabetic nephropathy. Exp. Nephrol. 5:180-188.
83. Bollineni, J.S., Alluru, I., and Reddi, A.S. 1997. Heparan sulfate proteoglycan synthesis and its expression are decreased in the retina of diabetic rats. Curr. Eye Res. 16:127-130.
84. Yokoyama, H., et al. 1997. Immunohistochemical quantification of heparan sulfate proteoglycan and collagen IV in skeletal muscle capillary basement membranes of patients with diabetic nephropathy. Diabetes. 46:1875-1880.
85. Kanwar, Y.S., et al. 1996. D-glucose-induced dysmorphogenesis of embryonic kidney. J. Clin. Invest. 98:2478-2488.
86. Templeton, D.M., and Fan, M.Y. 1996. Posttranscriptional effects of glucose on proteoglycan expression in mesangial cells. Metabolism. 45:1136-1146.
87. Jensen, T. 1997. Pathogenesis of diabetic vascular disease: evidence for the role of reduced heparan sulfate proteoglycan. Diabetes. 46(Suppl. 2):S98-S100.
88. Kjellen, L., Bielefeld, D., and Hook, M. 1983. Reduced sulfation of heparin sulfate in experimentally diabetic rats. Diabetes. 32:337-342.
89. Spiro, M.J. 1987. Sulfate metabolism in the alloxan-diabetic rat: relationship of altered sulfate pools to proteoglycan sulfation in heart and other tissues. Diabetologia. 30:259-267.
90. Unger, E., Pettersson, I., Eriksson, U.J., Lindahl, U., and Kjellen, L. 1991. Decreased activity of the heparan sulfate-modifying enzyme glucosaminyl N-deacetylase in hepatocytes from streptozotocin-diabetic rats. J. Biol. Chem. 266:8671-8674.
91. Curtin, A., et al. 1996. Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprorein B-48. Acta Diabetol. 33:205-210.